Technical Analysis for LQDA - Liquidia Technologies, Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
C | 10.63 | -0.93% | -0.10 |
Earnings due: Nov 13
*** please verify all earnings dates ***ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Down | Up | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Bollinger Band Squeeze | Range Contraction | 0.00% | |
NR7 | Range Contraction | 0.00% | |
Bearish Engulfing | Bearish | -0.93% | |
Fell Below 20 DMA | Bearish | -0.93% | |
Bollinger Band Squeeze | Range Contraction | -0.93% | |
Crossed Above 20 DMA | Bullish | -3.63% | |
Bollinger Band Squeeze | Range Contraction | -3.63% | |
Up 3 Days in a Row | Strength | -3.63% | |
Bollinger Band Squeeze | Range Contraction | -1.85% | |
Lower Bollinger Band Walk | Weakness | -1.85% |
Alert | Time |
---|---|
Possible NR7 | about 4 hours ago |
10 DMA Resistance | about 6 hours ago |
Down 2 % | about 6 hours ago |
60 Minute Opening Range Breakdown | about 6 hours ago |
Down 1% | about 7 hours ago |
Get this analysis on your stocks daily!
- Earnings date: 11/13/2024
Liquidia Technologies, Inc. Description
Liquidia Technologies, Inc. (“Liquidia”) is a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT® technology to transform the lives of patients. PRINT® is a particle engineering platform that enables precise production of uniform drug particles designed to improve the safety, efficacy and performance of a wide range of therapies. Currently, Liquidia is focused on the development of two product candidates for which it holds worldwide commercial rights: LIQ861 for the treatment of pulmonary arterial hypertension and LIQ865 for the treatment of local post-operative pain. Liquidia’s lead product candidate, LIQ861, currently being evaluated in a Phase 3 clinical trial (INSPIRE), is designed to improve the therapeutic profile of treprostinil by enhancing deep-lung delivery and achieving higher dose levels than current inhaled therapies by using a convenient, disposable dry powder inhaler. LIQ865, for which Liquidia has recently completed a U.S. Phase 1b clinical trial, is designed to deliver sustained-release particles of bupivacaine, a non-opioid anesthetic, to treat local post-operative pain for three to five days through a single administration. In addition to developing its own product candidates, Liquidia collaborates with leading pharmaceutical companies to develop their own product candidates across a wide range of therapeutic areas, molecule types and routes of administration, leveraging Liquidia’s PRINT® technology.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Life Sciences Pharmaceutical Pain Medication Hypertension Opioids Clinical Trial Uniform Pulmonary Arterial Hypertension Bupivacaine Inhaler Treprostinil
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 16.99 |
52 Week Low | 6.0993 |
Average Volume | 910,622 |
200-Day Moving Average | 12.42 |
50-Day Moving Average | 10.46 |
20-Day Moving Average | 10.97 |
10-Day Moving Average | 10.76 |
Average True Range | 0.40 |
RSI (14) | 46.24 |
ADX | 25.05 |
+DI | 23.18 |
-DI | 18.76 |
Chandelier Exit (Long, 3 ATRs) | 10.63 |
Chandelier Exit (Short, 3 ATRs) | 11.38 |
Upper Bollinger Bands | 11.54 |
Lower Bollinger Band | 10.39 |
Percent B (%b) | 0.21 |
BandWidth | 10.55 |
MACD Line | 0.00 |
MACD Signal Line | 0.06 |
MACD Histogram | -0.056 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 11.09 | ||||
Resistance 3 (R3) | 11.10 | 10.96 | 11.01 | ||
Resistance 2 (R2) | 10.96 | 10.84 | 10.95 | 10.99 | |
Resistance 1 (R1) | 10.79 | 10.77 | 10.72 | 10.78 | 10.96 |
Pivot Point | 10.65 | 10.65 | 10.62 | 10.65 | 10.65 |
Support 1 (S1) | 10.49 | 10.54 | 10.42 | 10.48 | 10.30 |
Support 2 (S2) | 10.35 | 10.46 | 10.34 | 10.27 | |
Support 3 (S3) | 10.18 | 10.35 | 10.25 | ||
Support 4 (S4) | 10.17 |